Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 23;8(12):ofab559.
doi: 10.1093/ofid/ofab559. eCollection 2021 Dec.

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Samuel Pierre  1 , Iryna Bocharova  2 , Catherine Nguyen  2 , Fabienne Homeus  1 , Gaetane Julmiste  1 , Youry Macius  1 , Vanessa Rouzier  1   3 , Patrice Severe  1 , Marie Marcelle Deschamps  1 , Colette Guiteau Moise  1 , Clovy Bellot  1 , Johnny Wu  2 , Vanessa R Rivera  1   3 , Rochelle Sun  2 , Jean W Pape  1   3 , Bernard Liautaud  1 , Serena P Koenig  4
Affiliations

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Samuel Pierre et al. Open Forum Infect Dis. .

Abstract

We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.

Keywords: HIV; genotypic resistance; second-line therapy; tenofovir disoproxil fumarate; zidovudine.

PubMed Disclaimer

References

    1. World Health Organization. Update of recommendations on first-and second-line antiretroviral regimens. 2019. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.1.... Accessed 3 May 2021.
    1. TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis 2016; 16:565–75. - PMC - PubMed
    1. La Rosa AM, Harrison LJ, Taiwo B, et al. . ACTG A5273 Study Group. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 2016; 3:e247–58. - PMC - PubMed
    1. Paton NI, Kityo C, Thompson J, et al. . Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Lancet HIV 2017; 4:e341–8. - PMC - PubMed
    1. Paton NI, Kityo C, Hoppe A, et al. . EARNEST Trial Team. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234–47. - PubMed